Flow Cytometry in Differential Diagnosis of Nodal Lymphomas Flow Cytometry in Differential Diagnosis of Nodal Lymphomas
How can flow cytometry be used for differentiating between between follicular lymphoma and diffuse large B-cell lymphoma/high-grade B-cell lymphoma?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 25, 2020 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
Risk factors for keratinocyte carcinomas were associated with the risk of developing non-Hodgkin lymphomas and chronic lymphocytic leukemia in an analysis of 92,097 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

What are Potential Problems Associated with Helicobacter pylori?
Discussion Helicobacter pylori (H. pylori) is a microaerophilis, spiral bacterium that is a prevalent human pathogen. How this infection affects individuals is different in adults and children. Overall seroprevalence rate in children world-wide was estimated to be ~33%, but this seroprevalence rate is decreasing in the developed world for both adults and children. It is acquired in childhood and can persist through colonization throughout life if untreated. Fortunately, it often is asymptomatic and generally does not cause serious disease in children. Some serotyping data shows that within families children acquire it more...
Source: PediatricEducation.org - November 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Rates of VTE, Major Bleeding High in Primary CNS Lymphoma
Pulmonary embolism and major bleeding linked to increased mortality risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 20, 2020 Category: Cancer & Oncology Tags: Neurology, Oncology, Pharmacy, Pulmonology, Radiology, Journal, Source Type: news

Rates of VTE, Major Bleeding High in Primary CNS Lymphoma
FRIDAY, Nov. 20, 2020 -- For patients with primary central nervous system lymphoma (PCNSL), the incidence of venous thromboembolism (VTE) and major bleeding is high, according to a study published in the November issue of Leukemia&... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2020 Category: Pharmaceuticals Source Type: news

End of Life Care in Lymphoma Compromised by Late Recognition of Dying End of Life Care in Lymphoma Compromised by Late Recognition of Dying
Recognition of dying was only made a day before death in half of lymphoma patients, shows a study aimed at understanding more about end of life care in this group of patients that often deteriorate rapidly.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Hodgkin's vs. Non-Hodgkin's Lymphoma
Title: Hodgkin's vs. Non-Hodgkin's LymphomaCategory: Diseases and ConditionsCreated: 1/31/2007 12:00:00 AMLast Editorial Review: 11/10/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 10, 2020 Category: Cancer & Oncology Source Type: news

The natural artistry of disease: a wintry landscape in the eye
(Tokyo Medical and Dental University) Researchers from Tokyo Medical and Dental University (TMDU) report a case of frosted branch angiitis in a woman presenting years after being treated for leukemia-lymphoma with allogeneic human stem cell transplant. The relevance of this ocular finding is discussed and its value as an early warning sign of immune activation following therapeutic immunological interventions is highlighted. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2020 Category: Cancer & Oncology Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Media News - November 5, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Investor Update - November 5, 2020 Category: Pharmaceuticals Source Type: news

CAR T for All R/R DLBCL Patients: The Jury Is Still Out CAR T for All R/R DLBCL Patients: The Jury Is Still Out
Is it time to consider chimeric antigen receptor (CAR) T-cell therapy for all relapsed/refractory diffuse large B-cell lymphoma patients? Maybe not, according to Andrew Zelenetz, MD, PhD.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 28, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Upped Risk of Death From Other Causes After Hodgkin Lymphoma Upped Risk of Death From Other Causes After Hodgkin Lymphoma
Compared with the general population, survivors of Hodgkin lymphoma have a significantly higher mortality risk from noncancer and cancers other than lymphomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 27, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oncotarget: An integrative microenvironment approach for follicular lymphoma
(Impact Journals LLC) Oncotarget Volume 11, Issue 33 features Figure 8, " Haplotype estimates in follicular lymphoma patients, " by Assis-Mendon ç a, et al. which reported that the authors tested associations between SNPs, clinicopathological features and TME composition, and proposed survival models in R-CHOP/R-CVP-treated patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2020 Category: Cancer & Oncology Source Type: news

“The Dude” Has Cancer: Five Things To Know About Lymphoma
Hollywood legend, Jeff Bridges, announced his diagnosis of lymphoma. This 'liquid tumor' is still a mystery to the public. Here are 5 key things to know about lymphoma. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 26, 2020 Category: Pharmaceuticals Authors: Lipi Roy, MD, MPH, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Actor Jeff Bridges Shares Lymphoma Diagnosis
Title: Actor Jeff Bridges Shares Lymphoma DiagnosisCategory: Health NewsCreated: 10/20/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 21, 2020 Category: Cancer & Oncology Source Type: news

Actor Jeff Bridges Shares Lymphoma Diagnosis
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 20, 2020 Category: Cancer & Oncology Tags: Nursing, Oncology, News, Source Type: news

Actor Jeff Bridges Shares Lymphoma Diagnosis
TUESDAY, Oct. 20, 2020 -- Actor Jeff Bridges announced on Monday that he has been diagnosed with lymphoma. Telling his fans on Twitter, the acclaimed thespian said, " Although it is a serious disease, I feel fortunate that I have a great team of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 20, 2020 Category: General Medicine Source Type: news

Actor Jeff Bridges being treated for lymphoma
Famous for his role of The Dude in The Big Lebowski, Bridges says the disease is serious but his prognosis is good (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Jeff Bridges announces he was diagnosed with lymphoma
The actor made the announcement on Twitter Monday. (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

FX & ‘The Old Man’ Producers React To Jeff Bridges’ Lymphoma Diagnosis: “We Are All In This Together With You”
Jeff Bridges, who this evening revealed that he has been diagnosed with lymphoma, has been filming FX on Hulu’s The Old Man in his... (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Jeff Bridges says he's been diagnosed with lymphoma
The Oscar-winning actor said he's starting treatment and the "prognosis is good." (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Jeff Bridges Announces Lymphoma Diagnosis
Actor Jeff Bridges announced on Twitter Monday afternoon that he has been diagnosed with lymphoma. He started his post off with a... (Source: Reuters: Health)
Source: Reuters: Health - October 20, 2020 Category: Consumer Health News Source Type: news

Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines Diagnosing Hodgkin Lymphoma in Kids Requires Biopsy, Immunohistochemistry: Guidelines
The diagnosis of pediatric Hodgkin lymphoma requires an excisional or incisional biopsy and immunohistochemistry (IHC) evaluation, and its management depends largely on the clinical stage and risk group, according to new guidelines from the National Comprehensive Cancer Network (NCCN).Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 19, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma EMA OKs First CAR T-Cell Therapy for Mantle Cell Lymphoma
Brexucabtagene autoleucel (Tecartus) is a new cell therapy product and the only one with an indication for this particular hematological malignancy.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA extends approval of pembrolizumab for classical Hodgkin lymphoma
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 15, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Expanded Indication for Merck ’s Keytruda (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
KENILWORTH, N.J.--(BUSINESS WIRE) October 15, 2020 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for Keytruda, Merck’s... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 15, 2020 Category: Drugs & Pharmacology Source Type: news

14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
(American Association for Cancer Research) The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 14, 2020 Category: Cancer & Oncology Source Type: news

Relationship Explored Between Physical Activity and Lymphoma
TUESDAY, Oct. 13, 2020 -- High levels of physical activity may lower the risk for developing lymphoma, according to a review/meta-analysis published online Oct. 6 in BMC Cancer. Gwynivere A. Davies, M.D., M.P.H., from the Juravinski Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 13, 2020 Category: Pharmaceuticals Source Type: news

Anticancer compounds for B cell cancer therapy targeting cellular stress response
(The Wistar Institute) Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2020 Category: Biology Source Type: news

New radioimmunotherapy improves lymphoma treatment
Researchers have found that a new radioimmunotherapy can reverse resistance...Read more on AuntMinnie.comRelated Reading: New radiotracer increases multiple myeloma survival PET/CT pinpoints Hodgkin's lymphoma treatment response PET rules out need for radiotherapy in lymphoma patients Radioimmunotherapy shows promise for curing HIV infection SNMMI touts radioimmunotherapy study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 9, 2020 Category: Radiology Source Type: news

Latest T-Cell Clinical Trial Opens for Mesothelioma Patients
Memorial Sloan Kettering Cancer Center in New York City has begun recruiting patients with pleural mesothelioma for its latest — and potentially most promising — clinical trial involving T-cell therapy. The novel study stems from the U.S. Food and Drug Administration’s recent Investigational Drug Application approval of ATA2271, a chimeric antigen receptor known as CAR T-cell therapy. This latest therapy will be tested in a phase I, dose-escalation clinical trial. It will involve the removal and genetic modification of a patient’s T cells, a type of white blood cell, that will be separated in the la...
Source: Asbestos and Mesothelioma News - October 8, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

Many Non-Hodgkin's Lymphoma patients can skip radiation, collaborative study finds
(University of Arizona Health Sciences) Skipping radiation and receiving less chemotherapy may become the new standard of care for some lymphoma patients, according to a recent collaborative University of Arizona Health Sciences-led study. Published in the Journal of Clinical Oncology, the study suggests using a positron emission tomography (PET) scan after three cycles of a combination of chemotherapy drugs known as R-CHOP. If the patient's scan is negative, they can proceed with another round of R-CHOP to complete their treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news

7 Things to Know About New Lymphoma Drug Tafasitamab 7 Things to Know About New Lymphoma Drug Tafasitamab
Lymphoma specialist Ann LaCasce, MD, discusses tafasitamab-cxix, the recently approved treatment for patients with relapsed/refractory disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in in patients with large B-cell lymphoma
(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to treatment and develop side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2020 Category: Cancer & Oncology Source Type: news

FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

Adding polatuzumab vedotin cost effective in large B-cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2020 Category: Drugs & Pharmacology Source Type: news

Economic and QOL evidence scarce in mantle cell lymphoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2020 Category: Drugs & Pharmacology Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Maximizing cures and minimizing side effects in children with Hodgkin lymphoma
(National Comprehensive Cancer Network) The National Comprehensive Cancer Network (NCCN) announces publication of new NCCN Guidelines for Pediatric Hodgkin Lymphoma. Hodgkin lymphoma is one of the most curable forms of pediatric cancer, with long-term survival rates of 90% or higher . However, treatment can result in potentially life-threatening or -altering long-term side effects. These new recommendations from NCCN synthesize the latest evidence and expert-consensus to make sure every child receives appropriate, but not excessive, treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2020 Category: Cancer & Oncology Source Type: news

Can Lymphoma Be Completely Cured?
Title: Can Lymphoma Be Completely Cured?Category: Diseases and ConditionsCreated: 9/24/2020 12:00:00 AMLast Editorial Review: 9/24/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 24, 2020 Category: Cancer & Oncology Source Type: news

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
LAUSANNE, Switzerland--(BUSINESS WIRE)-- September 24, 2020 -- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 24, 2020 Category: Drugs & Pharmacology Source Type: news

Penn researchers discover potential cause of immunotherapy-related neurotoxicity
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

Stop Livin to make lymphoma cells stop living
(University of Tsukuba) Researchers at the University of Tsukuba have shown that the protein Livin, an inhibitor of apoptosis or programmed cell death, mediates resistance to immunotherapy in some lymphoma variants. Therapeutically targeting Livin with IAP inhibitors or BET inhibitors may provide a practical strategy for patients with Livin-positive and other refractory B-cell lymphomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 16, 2020 Category: Cancer & Oncology Source Type: news

The Josep Carreras Institute identifies a marker of poor evolution in Hodgkin's lymphoma
(Josep Carreras Leukaemia Research Institute) Dr. Manel Esteller, director of the Josep Carreras Leukemia Research Institute, published today in Blood journal, the discovery of a marker that allows predicting which patient with Hodgkin's lymphoma will present the aggressive clinical course, and will therefore be a case of special risk. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Causes of Lymphoma and Its Action in the Body
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 11, 2020 Category: General Medicine Source Type: news

Mantle Cell Lymphoma: Identifying Patients With Indolent Disease Mantle Cell Lymphoma: Identifying Patients With Indolent Disease
Biomarkers are key in distinguishing between high-risk and indolent cases, allowing the latter to avoid unnecessary initial treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news